<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576575</url>
  </required_header>
  <id_info>
    <org_study_id>201104146</org_study_id>
    <nct_id>NCT01576575</nct_id>
  </id_info>
  <brief_title>Buprenorphine Disposition and CYP3A</brief_title>
  <official_title>Influence of CYP3A Modulation on Buprenorphine Disposition and Clinical Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate role of CYP3A in buprenorphine disposition and effect
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be studied during a maximum of seven occasions.

      Study drugs are intravenous buprenorphine (0.025-0.2 mg infused over 1 hr) and sublingual
      buprenorphine (2-4 mg), with 1-3 week washout between sessions.

      Sessions 1&amp;2: Control (no pretreatment) - intravenous and sublingual buprenorphine. Some
      subjects will only undergo session 1 (IV)

      Sessions 3&amp;4: Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and
      sublingual buprenorphine

      Session 5: Gut only CYP3A inhibition (grapefruit juice the night before), sublingual
      buprenorphine

      Sessions 6&amp;7: Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and
      sublingual buprenorphine
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 29, 2014</completion_date>
  <primary_completion_date type="Actual">March 29, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Cmax of Buprenorphine</measure>
    <time_frame>96 hr</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Healthy males and non-pregnant females</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be studied during a maximum of seven occasions.
Study drugs are intravenous buprenorphine (0.025-0.2 mg infused over 1 hr) and sublingual buprenorphine (2-4 mg), with 1-3 week washout between sessions.
Sessions 1&amp;2: Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)
Sessions 3&amp;4: Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine
Session 5: Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine
Sessions 6&amp;7: Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine Control</intervention_name>
    <description>Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)</description>
    <arm_group_label>Healthy males and non-pregnant females</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine + Rifampin</intervention_name>
    <description>Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine</description>
    <arm_group_label>Healthy males and non-pregnant females</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine + Grapefruit juice</intervention_name>
    <description>Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine</description>
    <arm_group_label>Healthy males and non-pregnant females</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine + Ketoconazole</intervention_name>
    <description>Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine</description>
    <arm_group_label>Healthy males and non-pregnant females</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each subject must meet all of the following criteria:

          1. Male or non-pregnant female volunteer, 18-50 yr old

          2. Good general health with no known major medical conditions

          3. BMI &lt; 33

          4. Provide informed consent

        Exclusion Criteria:

        Subjects will not be enrolled if any of the following criteria exist:

          1. Known history of liver or kidney disease

          2. Use of prescription or non-prescription medications, herbals or foods known to be
             metabolized by or affect CYP3A activity (this includes the use of oral
             contraceptives).

          3. Females who are pregnant or nursing

          4. Known history of drug or alcohol addiction (prior or present addiction or addiction
             treatment)

          5. Direct physical access to and routine handling of addicting drugs in the regular
             course of duty (this is a routine exclusion from studies of drugs with addiction
             potential)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Kharasch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1979 Feb;17(2):81-110. Review.</citation>
    <PMID>378645</PMID>
  </reference>
  <reference>
    <citation>Pickworth WB, Johnson RE, Holicky BA, Cone EJ. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther. 1993 May;53(5):570-6.</citation>
    <PMID>8491067</PMID>
  </reference>
  <reference>
    <citation>Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther. 1995 Jul;274(1):361-72.</citation>
    <PMID>7542336</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <results_first_submitted>June 20, 2018</results_first_submitted>
  <results_first_submitted_qc>January 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2020</results_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>buprenorphine CYP3A</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Volunteers</title>
          <description>Healthy males and non-pregnant females</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Buprenorphine Control</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Buprenorphine + Rifampin</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Buprenorphine + Grapefruit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Buprenorphine + Ketoconazole</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Volunteers</title>
          <description>Subjects will be studied during a maximum of seven occasions.
Study drugs are intravenous buprenorphine (0.025-0.2 mg infused over 1 hr) and sublingual buprenorphine (2-4 mg), with 1-3 week washout between sessions.
Sessions 1&amp;2: Control (no pretreatment) – intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)
Sessions 3&amp;4: Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine
Session 5: Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine
Sessions 6&amp;7: Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Cmax of Buprenorphine</title>
        <time_frame>96 hr</time_frame>
        <population>0 participants analyzed. The PI has left the institution. Sincere efforts were made to contact the PI but were unsuccessful. No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Control (no Pretreatment)</title>
            <description>Sessions 1&amp;2: Control (no pretreatment) – intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)</description>
          </group>
          <group group_id="O2">
            <title>Rifampin</title>
            <description>Sessions 3&amp;4: Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine</description>
          </group>
          <group group_id="O3">
            <title>Grapefruit Juice</title>
            <description>Session 5: Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine</description>
          </group>
          <group group_id="O4">
            <title>Ketoconazole</title>
            <description>Sessions 6&amp;7: Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cmax of Buprenorphine</title>
          <population>0 participants analyzed. The PI has left the institution. Sincere efforts were made to contact the PI but were unsuccessful. No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 96 hours following dosing</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control (no Pretreatment)</title>
          <description>Sessions 1&amp;2: Control (no pretreatment) – intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)</description>
        </group>
        <group group_id="E2">
          <title>Liver and Gut CYP3A Induction</title>
          <description>Sessions 3&amp;4: Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine</description>
        </group>
        <group group_id="E3">
          <title>Gut Only CYP3A Inhibition</title>
          <description>Session 5: Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine</description>
        </group>
        <group group_id="E4">
          <title>Liver and Gut CYP3A Inhibition</title>
          <description>Sessions 6&amp;7: Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <description>Adverse Event Reporting Description by Arms/Groups are combined as individual results not available. Adverse events all due to buprenorphine not pretreatments</description>
                <counts group_id="E1" events="40" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E2" events="39" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E3" events="21" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E4" events="30" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>itch</sub_title>
                <description>Adverse Event Reporting Description by Arms/Groups are combined as individual results not available. Adverse events all due to buprenorphine not pretreatments</description>
                <counts group_id="E1" events="32" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E2" events="32" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E3" events="16" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E4" events="25" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E4" events="15" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizzyness</sub_title>
                <counts group_id="E1" events="15" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Evan Kharasch MD PhD</name_or_title>
      <organization>Washington University</organization>
      <phone>3143628796</phone>
      <email>kharasch@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

